United States: Healthcare Law Update: June 2017

Nathan Adams IV and Shannon Hartsfield Salimone are Partners and Eddie Williams III is Senior Counsel in the Tallahassee office

David Glynn is a Partner in the Boston office


Florida's Medicaid Third-Party Liability Act Pre-empted by Federal Law

By Eddie Williams

In Gallardo v. Dudek, Sec. of Florida Agency for Health Care Administration, No. 4:16cv116-MW/CAS, 2017 WL 1405166 (N.D Fla. April 18, 2017), the federal district court, by order on summary judgment, declared that the Medicaid Act prohibits the Florida Agency for Health Care Administration (AHCA) from seeking reimbursement of past Medicaid payments from portions of a recipient's settlement funds that represent future medical expenses. In addition, the court declared that the Medicaid Act prohibits AHCA from requiring a Medicaid recipient to affirmatively disprove the formula-based allocation under §409.910(17)(b), Florida Statutes, with clear and convincing evidence in order to successfully overcome the allocation. Although the plaintiff's lawsuit was valued at approximately $20 million, the case eventually settled for $800,000. AHCA asserted a lien against that cause of action for the amount it had expended for the plaintiff's past medical expenses: $862,688.77. Pursuant to the formula-based allocation under Florida's Medicaid Third-Party Liability Act, AHCA sought to recover approximately $300,000 from the settlement funds that represented both past and future medical expenses. The court ruled that the federal Medicaid Act, particularly the anti-lien and anti-recovery provisions, limits a state's powers to pursue recovery of funds paid on the recipient's behalf. Further, the limited exceptions to these provisions only allow AHCA to satisfy its lien from the portion of settlement that represents compensation for past medical expenses. The plaintiff also argued that Florida's Medicaid Third-Party Liability Act conflicts with and is pre-empted by federal law. The court agreed with this argument where Medicaid recipients are required to affirmatively disprove the formula-based allocation with clear and convincing evidence to successfully overcome it. The court ruled that "an irrebuttable, one-size-fits-all statutory presumption that a pre-determined percentage of the recipient's recovery constitutes payment for medical care" does not comply with the federal Medicaid Act.


Drug Manufacturer's Alleged Misrepresentations Not Material to Public Payment

By Nathan Adams

In United States ex rel. Petratos v. Genentech, Inc., 855 F. 3d 481 (3d Cir. 2017), the court of appeals ruled that a qui tam relator failed sufficiently to allege that a drug manufacturer made misrepresentations that were material to the government's payment decision, as required to state a False Claims Act (FCA) claim. Relator Gerasimos Petratos was head of healthcare data analytics for Genentech. He alleged that his former employer suppressed data that caused doctors to certify incorrectly that Avastin was "reasonable and necessary" for certain at-risk Medicare patients; however, the relator disclosed this data to the U.S. Food and Drug Administration (FDA) and Department of Justice (DOJ) in 2010 and 2011. The FDA continued its approval of Avastin for the at-risk populations, whom Petratos claims the data adversely affects, and added three more approved indications for the drug. DOJ took no action against Genentech and declined to intervene in this suit. As a result, the court ruled that the alleged misrepresentations were not material to the government's payment decision and would have paid the claims with full knowledge of the alleged noncompliance. The court of appeals affirmed dismissal of the complaint.

Government Forced to Replead FCA/AKS Violations as to Each Defendant

By Nathan Adams

In United States of America v. D.S. Medical, LLC, No. 1:12CV00004 AGF, 2017 WL 2269006 (E.D. Mo. May 23, 2017), the court denied the government's motion for partial summary judgment in a qui tam action under the FCA for purported violations of the Anti-Kickback Statute (AKS). The operative complaint claims that the four defendants submitted or caused to be submitted to Medicare and Medicaid false claims for reimbursement for Dr. Sonjay Fonn's services in performing spinal surgeries at St. Francis Medical Center (SFMC) between December 2008 and March 2012, and for the purchase of implant devices used in those surgeries. According to the complaint, Dr. Fonn would select the devices he would use during surgeries at SFMC based, in part, on the fact that a company formed and created by his fiancée, D.S. Medical (DSM), would serve as the local distributor. DSM would then be paid commissions by the manufacturers, and DSM and Dr. Fonn's fiancée would share those commissions with Dr. Fonn. The court dismissed the complaint because the government's requested findings lumped all defendants together, when it is clear that not each proposed factual finding has been established as to each defendant, and because the civil penalties faced by defendants are on a per claim basis, making more precision important. The court denied the government's motion without prejudice to the government filing a new one.


Three Reminders About Refill Reminder Compliance

By David Glynn and Shannon Salimone

Specialty pharmacies, drug manufacturers and other members of the healthcare industry involved in refill reminder programs should be mindful that, while such programs are expressly permitted under HIPAA privacy rules, HIPAA does not endorse an "anything goes" approach. The U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) has made it clear that paying physicians and pharmacies to remind patients about refills of drugs they are currently taking is generally permissible under the HIPAA Privacy Rule. However, in addition to meeting the HIPAA requirements for such programs, companies must remember OCR's caveat that even a HIPAA-compliant program must adhere to the AKS, along with other fraud and abuse laws and regulations. Here are three things to keep in mind when structuring these programs:

First, if the pharmacy is getting paid to send reminders, it either needs to meet HIPAA's marketing exception or obtain written patient authorization. HIPAA generally requires a patient's written authorization if a healthcare provider or other covered entity will be using and disclosing protected health information (PHI) for "marketing," which includes communications about a drug that encourages the recipient to purchase or use the drug (i.e., refill reminders). If the pharmacy is not paid to send the refill reminder, it is not considered marketing under HIPAA. Otherwise, the pharmacy either needs the patient's written permission to make the call (which conforms to HIPAA's requirements for written authorizations), or the arrangement must meet HIPAA's marketing exception.

Second, HIPAA's exception for refill reminders restricts what a pharmacy can say and how much it can be paid. If a pharmacy or other covered entity gets paid for sending refill reminders, the arrangement must comply with certain parameters such as, without limitation, the following.

  • The reminder must be about a drug or biologic currently prescribed for the individual; i.e., a refill, not a new prescription, or another drug or formulation of the current drug.
  • The reminder can relate to generic equivalents of the prescribed drug, information about taking the prescribed drug as directed, discussions about a prescription that lapsed within the previous 90 calendar days or a delivery system for the drug, such as an insulin pump.
  • The payment for sending the reminder may cover only the reasonable direct and indirect costs related to the refill reminder, including labor, materials and supplies, and capital and overhead costs.

Notably, refill reminders required under FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) programs do not need to meet these requirements.

Third, the arrangement still has to comply with the AKS and other laws, such as the Stark Law. A manufacturer or healthcare provider is not necessarily in the clear from a regulatory perspective just because a refill reminder is permitted under HIPAA. Where a manufacturer pays a pharmacy to send refill reminders, the government will likely conclude that it implicates the AKS because one purpose of the payment is to induce the pharmacy to recommend or arrange for the purchase of its product. The HHS Office of Inspector General (OIG) has expressed a longstanding concern with payments to pharmacists for "recommending activity," due to its concern that "[i]n an era of aggressive drug marketing . . . patients may now be using prescription drug items, unaware that their physician or pharmacist is being compensated for promoting the selection of a specific product." OIG Special Fraud Alert (Dec. 19, 1994). In light of this, consider these points when structuring refill reminder arrangements.

  • Refill reminder arrangements should be structured to meet the personal services safe harbor, which requires, among other things, that the compensation be set in advance, and not fluctuate with the volume or value of any referrals generated by the arrangement.
  • The DOJ has made its position clear through a number of recent FCA cases and settlement agreements that refill reminder programs and other services that are paid for through discounts do not, in the DOJ's view, qualify for protection under the discount safe harbor or the personal services safe harbor.
  • Because no two arrangements are the same, it is wise to consult available advisory opinions (e.g., Advisory Opinion 11-17 addresses a refill reminder), other OIG guidance and relevant cases.

OCR has provided substantial guidance, including "frequently asked questions" on its website, that provide additional guidance on refill reminder programs. Specialty pharmacies, manufacturers and others wishing to structure refill reminder programs in a compliant manner should proceed with caution and with the advice of counsel.


Noerr-Pennington Doctrine Does Not Defeat Sherman Act in Event of Deception

By Nathan Adams

In Amphastar Pharmaceuticals, Inc. v. Momenta Pharmaceuticals, Inc., 850 F. 3d 52 (1st Cir. 2017), the court ruled that the mere fact that defendants brought patent infringement litigation resulting in an injunction against the plaintiffs did not immunize them from antitrust liability under the Noerr-Pennington doctrine, where the defendants allegedly made misrepresentations to the U.S. Pharmacopeial Convention (USP), a private standard-setting organization charged with ensuring the quality of drugs. According to the complaint, the defendants knowingly failed to disclose to the standard-setting body that a proposed method for testing generic enoxaparin might be covered by Momenta Pharmaceutical's pending patent application. The USP adopted the method, and the FDA required the plaintiff to comply with it. The plaintiff filed this Sherman Antitrust Act case seeking damages for profits lost during the pendency of the injunction. The district court dismissed the complaint under the Noerr-Pennington doctrine, which immunizes good faith petitioning of government entities from antitrust liability. The court of appeals reversed based on the alleged misrepresentation and remanded.

Deceptive Trade Practices

Pre-emption of State Failure-to-Warn Claims Left for Jury to Decide

By Nathan Adams

In In Re Fosamax (Alendronate Sodium) Products Liability Litigation, 852 F. 3d 268 (3d Cir. 2017), the court of appeals reversed summary judgment for the manufacturer on various state law failure-to-warn claims in connection with the manufacturer's failure to add a warning of risk of atypical femur fractures to the FDA-approved label for its osteoporosis drug. Merck Sharp & Dohme (Merck) made the FDA aware, prior to September 2010, that the drug could inhibit microdamage repair by preventing bone resorption at the sites of the damage and suggested adding warnings to both the "Warnings and Precautions" and the "Adverse Reactions" sections of the label to address atypical femoral fractures. In 2009, the FDA approved the addition of "low energy femoral shaft and subtrochanteric fractures" to the Adverse Reactions section, but rejected Merck's proposed addition to the Warnings and Precautions section. As part of this multidistrict litigation, plaintiffs insist that the FDA was objecting only to Merck's use of the imprecise and potentially misleading term "stress fractures" as part of the label, and would have approved a proposed warning that specifically discussed the risk of atypical femoral fractures, whereas Merck insists that the letter demonstrates that the FDA did not believe there was sufficient evidence of a causal link between drug use and atypical fractures, and would have rejected any proposed warning relating to such a risk. The issue is critical because if there is "clear evidence" that Merck's interpretation is correct, it pre-empts all state law claims. The court of appeals decided that this is a question of fact for the jury to decide.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.